Although VEGF-targeted therapies are now approved for the treatment of metastatic colorectal cancer, advanced lung cancer, renal cell carcinoma, metastatic breast cancer and glioblastoma [51,52,53,54,55], predictive markers for patient selection still remain elusive. This evidence concerns the gene VEGFA and lung carcinoma.